1. Are PAR exploring any non-dilutive forms of funding?
2. Assuming a shortfall in funding for the OA program, will PAR look to dial back on some of the other programs they do not expect will generate revenue/partnership deals in the near future?
3. Why did PAR not disclose to the market at an earlier time about the adverse tissue finding found in PPS-treated rats?
4. An update on the three other treatments PAR were looking to repurpose?
1. Are PAR exploring any non-dilutive forms of funding? 2....
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 33599 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 65498 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |